Plymouth Meeting-based INOVIO, a biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases, recently released its 2024 key accomplishments and its anticipated milestones for 2025.
“Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for patients suffering from a devastating rare disease and delivering on the promise of DNA medicines,” Dr. Jacqueline Shea, INOVIO president and CEO, said. “Our top priorities for the coming year are the submission of our biologics license application for INO-3107 and preparing to expedite the launch of the product commercially, should it be approved. We also look forward to making progress with our pipeline through collaborations and other potential strategic opportunities.”
INO-3107 is a DNA immunotherapy designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins.
In a trial of recurrent respiratory papillomatosis (RRP) patients, half of the participants treated with INO-3107 achieved a complete response (CR) and required no surgery when evaluated at the end of year two. The initial CR rate at the end of the first year was 28 percent.